Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) — Market Cap & Net Worth
Market Cap & Net Worth: Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) has a market capitalization of $3.89 Million ($3.89 Million) as of August 23, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29115 globally and #5933 in its home market, demonstrating a -3.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lakewood-Amedex Biotherapeutics Inc. Common Stock's stock price $2.24 by its total outstanding shares 1750657 (1.75 Million). See debt-free asset ratio of Lakewood-Amedex Biotherapeutics Inc. Com to understand what proportion of total assets are financed by equity.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Market Cap History: 2026 to 2026
Lakewood-Amedex Biotherapeutics Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $3.92 Million to $3.92 Million (0.00% CAGR). Also see how large is Lakewood-Amedex Biotherapeutics Inc. Com's balance sheet for a full breakdown of the balance sheet.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lakewood-Amedex Biotherapeutics Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Lakewood-Amedex Biotherapeutics Inc. Com stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LABT by Market Capitalization
Companies near Lakewood-Amedex Biotherapeutics Inc. Common Stock in the global market cap rankings as of August 23, 2026. Also see Lakewood-Amedex Biotherapeutics Inc. Com cash conversion from operations for how efficiently the company converts equity into cash flow.
Key companies related to Lakewood-Amedex Biotherapeutics Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Lakewood-Amedex Biotherapeutics Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Lakewood-Amedex Biotherapeutics Inc. Common Stock's market cap moved from $3.92 Million to $ 3.92 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.92 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 23rd, 2026 the market cap of Lakewood-Amedex Biotherapeutics Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.89 Million USD |
| MoneyControl | $3.89 Million USD |
| MarketWatch | $3.89 Million USD |
| marketcap.company | $3.89 Million USD |
| Reuters | $3.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic f… Read more